Evidence map›Paper›PMID 40594383›Full record

ArticleScientific reports2025

Trimetazidine stimulates intracellular Ca

Sara Bernardi, Sara Vitolo, Chiara Gabellini, Maria Marchese, Elisabetta Ferraro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara Bernardi *Neurobiology and Molecular Medicine Unit, IRCCS Fondazione Stella Maris, Via dei Giacinti, 2, Calambrone, Pisa, 56128, Italy.
Sara Vitolo *Department of Biology, Unit of Cellular, Molecular and Developmental Biology, University of Pisa, S.S. 12 Abetone e Brennero 4, Pisa, 56127, Italy.
Chiara GabelliniDepartment of Biology, Unit of Cellular, Molecular and Developmental Biology, University of Pisa, S.S. 12 Abetone e Brennero 4, Pisa, 56127, Italy.
Maria Marchese *Neurobiology and Molecular Medicine Unit, IRCCS Fondazione Stella Maris, Via dei Giacinti, 2, Calambrone, Pisa, 56128, Italy.
Elisabetta Ferraro *Department of Biology, Unit of Cellular, Molecular and Developmental Biology, University of Pisa, S.S. 12 Abetone e Brennero 4, Pisa, 56127, Italy. elisabetta.ferraro@unipi.it.

Funding

AFM-TELETHON AFM 23771PRIN 2022 PNRR P2022LSW98Telethon Foundation GSA23C003
6 · The paper itself

Abstract

The metabolic modulator trimetazidine (TMZ) is an antianginal recently found to improve skeletal muscle performance in mice models of sarcopenia and of amyotrophic lateral sclerosis (ALS). The mechanism underlying the effect of TMZ on locomotor activity has been proposed to rely on its ability to enhance metabolic efficiency with a consequent improvement of myogenesis and of neuromuscular junction (NMJ) and muscle function. However, although promising and therefore under clinical trials, the mechanism of action of TMZ has not been clearly disclosed; here we hypothesized that it might involve the modulation of neuronal Ca

Indexed as

CalciumCalcium SignalingLocomotionMotor NeuronsSpinal CordTrimetazidineAnimalsAnimals, Genetically ModifiedZebrafishCalciumTrimetazidineAgingAmyotrophic lateral sclerosisMotor neuron diseaseNeuro-muscular junctionSkeletal muscleSpinal cordTrimetazidine

Identifiers

PMID40594383
PMCPMC12214544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.